Carregant...
Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers
AIMS: Interindividual differences in the pharmacokinetics of venlafaxine, a new antidepressant, were shown during early clinical trials in Japan. Venlafaxine is metabolized mainly by CYP2D6 to an active metabolite, O-desmethylvenlafaxine (ODV). Therefore, the influence of the CYP2D6 genotypes on ven...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Blackwell Science Inc
1999
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2014246/ https://ncbi.nlm.nih.gov/pubmed/10233212 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1046/j.1365-2125.1999.00913.x |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|